Feng Ren

Director Ejecutivo en Insilico Medicine Cayman TopCo .

49 años

Consumer Services

Commercial Services

Perfil

Feng Ren is currently the Co-Chief Executive Officer & Executive Director at InSilico Medicine Cayman TopCo. Prior to this, he obtained a doctorate degree from Harvard University in 2007.
He also holds a graduate degree from the National University of Singapore, which he received in 2004.
Dr. Ren completed his undergraduate studies at the University of Science & Technology of China in 1998.

Cargos activos de Feng Ren

Empresas	Cargo	Inicio
Insilico Medicine Cayman TopCo Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.	Director Ejecutivo	01/06/2022

Todos los cargos activos de Feng Ren

Formación de Feng Ren.

University of Science & Technology of China	Undergraduate Degree
National University of Singapore	Graduate Degree
Harvard University	Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Feng Ren.

Relaciones

100 +

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	1
Insilico Medicine Cayman TopCo Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.	Commercial Services